NCT02515331 - Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2015

Primary Completion Date

August 17, 2017

Study Completion Date

August 17, 2017

Conditions

Patients, Resistant Hypertension

Interventions

DRUG

LHW090

Capsule - oral dose

DRUG

Placebo

Capsule - oral dose

Trial Locations (16)

1011

Novartis Investigative Site, Lausanne

4031

Novartis Investigative Site, Basel

10098

Novartis Investigative Site, Berlin

30625

Novartis Investigative Site, Hanover

32117

Novartis Investigative Site, Daytona Beach

32216

Novartis Investigative Site, Jacksonville

33462

Novartis Investigative Site, Atlantis

35294

Novartis Investigative Site, Birmingham

37920

Novartis Investigative Site, Knoxville

40225

Novartis Investigative Site, Düsseldorf

66421

Novartis Investigative Site, Homburg

75015

Novartis Investigative Site, Paris

91606

Novartis Investigative Site, North Hollywood

96814

Novartis Investigative Site, Honolulu

DK 2820

Novartis Investigative Site, Gentofte Municipality

1105 AZ

Novartis Investigative Site, Meibergdreef 9